Fmr LLC decreased its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 7.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,461,150 shares of the biopharmaceutical company’s stock after selling 194,955 shares during the quarter. Fmr LLC owned about 2.41% of Sangamo Therapeutics worth $28,254,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SGMO. JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock worth $1,792,000 after acquiring an additional 7,817 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Sangamo Therapeutics by 1.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 454,735 shares of the biopharmaceutical company’s stock worth $7,708,000 after acquiring an additional 7,472 shares during the period. BlackRock Inc. lifted its stake in shares of Sangamo Therapeutics by 3.0% in the 3rd quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock worth $141,063,000 after acquiring an additional 239,190 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth $3,755,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth $279,000. 62.50% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SGMO opened at $11.70 on Monday. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.08. Sangamo Therapeutics Inc has a 52 week low of $6.26 and a 52 week high of $20.15. The stock has a market capitalization of $1.20 billion, a P/E ratio of -16.71 and a beta of 2.84.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Sangamo Therapeutics had a negative net margin of 80.92% and a negative return on equity of 20.75%. The firm had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $24.54 million. As a group, research analysts anticipate that Sangamo Therapeutics Inc will post -1.23 EPS for the current fiscal year.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $12.11, for a total transaction of $60,550.00. Following the completion of the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at approximately $369,500.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 15,000 shares of company stock valued at $160,550 over the last 90 days. 1.20% of the stock is currently owned by insiders.

SGMO has been the subject of several recent analyst reports. ValuEngine cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Wedbush set a $10.00 price objective on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Sunday, March 10th. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 25th. Finally, Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. One analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $16.40.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-holdings-decreased-by-fmr-llc/2980799.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Recommended Story: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.